Retatrutide + Cagrilintide May Be Showing Us What Comes After Triple Agonists

A new Nature Metabolism study may have given us one of the clearest looks yet at where obesity medicine is headed next. Researchers combined retatrutide, which targets GLP-1, GIP and glucagon receptors, with cagrilintide, which targets amylin and calcitonin receptors, effectively creating five-receptor pharmacology in obese male rats.